Zydelig

idelalisib

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR) for Zydelig. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Zydelig.

For practical information about using Zydelig, patients should read the package leaflet or contact their doctor or pharmacist.

What is Zydelig and what is it used for?

Zydelig is a cancer medicine that is used to treat two types of blood cancer: chronic lymphocytic leukaemia (a cancer of a type of white blood cells called B lymphocytes) and follicular lymphoma (one of another group of cancers that affect B lymphocytes).

In chronic lymphocytic leukaemia, Zydelig is used in combination with another medicine (rituximab) in patients who have received at least one previous treatment and in patients who have genetic mutations in their cancer cells called 17p deletion or TP53 mutation that make them unsuitable for treatment with a combination of chemotherapy medicines and immunotherapy (treatments that stimulate the immune system to kill cancer cells).

In follicular lymphoma, Zydelig is used in patients whose disease has not responded to two previous treatments.

Zydelig contains the active substance idelalisib.

How is Zydelig used?

Zydelig can only be obtained with a prescription and treatment should be prescribed by a doctor experienced in using cancer medicines.

Zydelig is available as 100 mg and 150 mg tablets. The recommended dose is 150 mg twice a day, and treatment should be continued for as long as the patient improves or remains stable and the side effects are tolerable. If the patient experiences severe side effects, treatment must be stopped and can be re-started at a lower dose of 100 mg twice a day.

For more information, see the summary of product characteristics (also part of the EPAR).

How does Zydelig work?

The active substance in Zydelig, idelalisib, blocks the effects of an enzyme called PI3K-delta. This enzyme plays a role in the growth, migration and survival of white blood cells but is overactive in blood cancers, where it enables the survival of the cancer cells. By targeting this enzyme and blocking its effects, idelalisib causes death of the cancer cells, thereby delaying or stopping the progression of the cancer.

What benefits of Zydelig have been shown in studies?

In a main study of 220 patients with previously treated chronic lymphocytic leukaemia, Zydelig was shown to be more effective at treating the cancer than placebo (a dummy treatment) when both were given in combination with another medicine rituximab: 75% of patients taking Zydelig had an improvement in their disease compared with 15% of patients taking placebo. Zydelig was also more effective than placebo in the subgroup of patients who had a specific genetic mutation in their cancer cells that makes them unsuitable for chemo-immunotherapy.

Another main study evaluated Zydelig in patients with different lymphomas, including 72 patients with follicular lymphoma that had failed two previous treatments. Zydelig was shown to be effective, with 54% of patients with follicular lymphoma having either a complete or partial response to treatment.

What are the risks associated with Zydelig?

The most common side effects with Zydelig (which may affect more than 1 in 10 people) are infections, neutropenia (low levels of neutrophils, a type of white blood cell), diarrhoea, increased liver enzymes in blood, rash, fever and increased blood fat levels.

Based on studies in animals, Zydelig may be harmful to the unborn child. Zydelig is therefore not recommended during pregnancy, and women taking the medicine should use a reliable method of contraception to avoid becoming pregnant during treatment and for 1 month after treatment. It is also not known whether Zydelig can make hormonal contraceptives less effective. Women and their partners should therefore also use a barrier method of contraception such as condoms.

For the full list of all side effects and restrictions, see the package leaflet.

Why is Zydelig approved?

The Agency’s Committee for Medicinal Products for Human Use (CHMP) noted that available data from the main studies, which were still ongoing at the time of the evaluation, showed high response rates with Zydelig in patients with chronic lymphocytic leukaemia and follicular lymphoma. It was also effective in chronic lymphocytic leukaemia patients who have the 17p deletion or TP53 mutation that makes them unsuitable for chemo-immunotherapy.

In addition, the safety of the medicine was considered acceptable. The Committee therefore concluded that Zydelig’s benefits are greater than its risks and recommended that it be approved for use in the EU.

What measures are being taken to ensure the safe and effective use of Zydelig?

A risk management plan has been developed to ensure that Zydelig is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Zydelig, including the appropriate precautions to be followed by healthcare professionals and patients.

In addition, the company will also provide final results of the ongoing main studies of Zydelig in patients with chronic lymphocytic leukaemia and follicular lymphoma.

Other information about Zydelig

The European Commission granted a marketing authorisation valid throughout the European Union for Zydelig on 18 September 2014.

For more information about treatment with Zydelig, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Name Language First published Last updated
Zydelig : EPAR - Summary for the public BG = bălgarski 14/10/2014  
Zydelig : EPAR - Summary for the public ES = español 14/10/2014  
Zydelig : EPAR - Summary for the public CS = čeština 14/10/2014  
Zydelig : EPAR - Summary for the public DA = dansk 14/10/2014  
Zydelig : EPAR - Summary for the public DE = Deutsch 14/10/2014  
Zydelig : EPAR - Summary for the public ET = eesti keel 14/10/2014  
Zydelig : EPAR - Summary for the public EL = elliniká 14/10/2014  
Zydelig : EPAR - Summary for the public EN = English 14/10/2014  
Zydelig : EPAR - Summary for the public FR = français 14/10/2014  
Zydelig : EPAR - Summary for the public IT = italiano 14/10/2014  
Zydelig : EPAR - Summary for the public LV = latviešu valoda 14/10/2014  
Zydelig : EPAR - Summary for the public LT = lietuvių kalba 14/10/2014  
Zydelig : EPAR - Summary for the public HU = magyar 14/10/2014  
Zydelig : EPAR - Summary for the public MT = Malti 14/10/2014  
Zydelig : EPAR - Summary for the public NL = Nederlands 14/10/2014  
Zydelig : EPAR - Summary for the public PL = polski 14/10/2014  
Zydelig : EPAR - Summary for the public PT = português 14/10/2014  
Zydelig : EPAR - Summary for the public RO = română 14/10/2014  
Zydelig : EPAR - Summary for the public SK = slovenčina 14/10/2014  
Zydelig : EPAR - Summary for the public SL = slovenščina 14/10/2014  
Zydelig : EPAR - Summary for the public FI = suomi 14/10/2014  
Zydelig : EPAR - Summary for the public SV = svenska 14/10/2014  
Zydelig : EPAR - Summary for the public HR = Hrvatski 14/10/2014  
Name Language First published Last updated
Zydelig : EPAR - Risk-management-plan summary (English only) 14/10/2014  

This EPAR was last updated on 27/05/2016 .

Authorisation details

Product details

Product details for Zydelig
NameZydelig
Agency product numberEMEA/H/C/003843
Active substance

idelalisib

International non-proprietary name (INN) or common name

idelalisib

Therapeutic area Lymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Anatomical therapeutic chemical (ATC) code L01XX47
Additional monitoring

This medicine is under additional monitoring. This means that it is being monitored even more intensively than other medicines. For more information, see medicines under additional monitoring.

Publication details

Publication details for Zydelig
Marketing-authorisation holder

Gilead Sciences International Ltd

Revision5
Date of issue of marketing authorisation valid throughout the European Union18/09/2014

Contact address:

Gilead Sciences International Ltd
Flowers Building 
Granta Park 
Abington 
Cambridge 
CB21 6GT 
United Kingdom

Product information

Product information

23/03/2016  Zydelig -EMEA/H/C/003843 -EMEA/H/A-20/1439/C/3843/0023

Name Language First published Last updated
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016
Zydelig : EPAR - Product Information EN = English 14/10/2014 07/06/2016

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  
Zydelig : EPAR - All Authorised presentations EN = English 14/10/2014  

Pharmacotherapeutic group

Antineoplastic agents, other antineoplastic agents

Therapeutic indication

Zydelig is indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL):

  • who have received at least one prior therapy, or
  • as first line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.

Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.

Assessment History

Changes since initial authorisation of medicine

Name Language First published Last updated
Zydelig : EPAR - Procedural steps taken and scientific information after authorisation EN = English 22/05/2015 27/05/2016

Initial marketing-authorisation documents

Name Language First published Last updated
Zydelig : EPAR - Public assessment report EN = English 14/10/2014  
CHMP summary of positive opinion for Zydelig EN = English 25/07/2014